BridgeBio Pharma Inc [BBIO] stock is trading at $75.69, up 1.58%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BBIO shares have gain 5.61% over the last week, with a monthly amount glided 14.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BridgeBio Pharma Inc [NASDAQ: BBIO] stock has seen the most recent analyst activity on December 11, 2025, when Bernstein initiated its Outperform rating and assigned the stock a price target of $94. On July 21, 2025, Truist initiated with a Buy rating and assigned a price target of $66 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $70 on July 14, 2025. Oppenheimer upgraded its rating to an Outperform but $60 remained the price target by the analyst firm on July 09, 2025. Wolfe Research started tracking with an Outperform rating for this stock on June 17, 2025, and assigned it a price target of $49. In a note dated March 31, 2025, Redburn Atlantic initiated a Buy rating and provided a target price of $50 on this stock.
BridgeBio Pharma Inc [BBIO] stock has fluctuated between $25.34 and $75.61 over the past year. Currently, Wall Street analysts expect the stock to reach $87.25 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $75.69 at the most recent close of the market. An investor can expect a potential return of 15.27% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 353.78M for the trailing twelve months, which represents a growth of 4318.01%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.72%, Pretax Profit Margin comes in at -2.27%, and Net Profit Margin reading is -2.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.8, Equity is 0.47 and Total Capital is -0.78. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 73.44 points at the first support level, and at 71.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 77.22, and for the 2nd resistance point, it is at 78.76.
Ratios To Look Out For
For context, BridgeBio Pharma Inc’s Current Ratio is 3.88. As well, the Quick Ratio is 3.76, while the Cash Ratio is 2.97. Considering the valuation of this stock, the price to sales ratio is 41.23.
Transactions by insiders
Recent insider trading involved Kumar Neil, Chief Executive Officer, that happened on Dec 15 ’25 when 30011.0 shares were sold. Director, NEIL KUMAR completed a deal on Dec 15 ’25 to buy 30011.0 shares. Meanwhile, Chief Accounting Officer Apuli Maricel sold 2000.0 shares on Dec 08 ’25.
